| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CORT | Common Stock | Options Exercise | $56.8K | +5K | +68.36% | $11.35 | 12.3K | Jun 3, 2024 | Direct | F1 |
| transaction | CORT | Common Stock | Sale | -$151K | -5K | -40.6% | $30.18 | 7.31K | Jun 3, 2024 | Direct | F1, F2, F3 |
| transaction | CORT | Common Stock | Tax liability | -$14.7K | -488 | -6.67% | $30.17 | 6.83K | Jun 3, 2024 | Direct | F1, F4, F5 |
| transaction | CORT | Common Stock | Award | $38.6K | +1.23K | +18.05% | $31.30 | 8.06K | Jun 3, 2024 | Direct | F1, F6, F7 |
| transaction | CORT | Common Stock | Award | $0 | +1.23K | +15.29% | $0.00 | 9.29K | Jun 3, 2024 | Direct | F1, F8 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CORT | Stock option (right to buy) | Options Exercise | $0 | -5K | -26.09% | $0.00 | 14.2K | Jun 3, 2024 | Common Stock | 5K | $11.35 | Direct | F9 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Includes 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| F2 | The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. |
| F3 | Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $30.17 to $30.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. |
| F4 | These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. |
| F5 | The closing price on May 31, 2024 was used to calculate the withholding obligation. |
| F6 | The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 3, 2024. |
| F7 | In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. |
| F8 | Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. |
| F9 | Fully exercisable. |
Chief Accounting & Technology Officer